Luxury brands rarely communicate about endocrine disruptors.
Instead, they talk about innovation, excellence, sustainability and product safety. LVMH is no exception. Through its LIFE 360 environmental programme, the world’s leading luxury group presents itself as a company that places scientific expertise, ingredient safety and environmental responsibility at the heart of product development. Its public commitments are substantial. They include toxicological assessment of raw materials, internal restricted substances lists, continuous scientific monitoring and the gradual substitution of chemicals considered hazardous or controversial.
There is little reason to question the seriousness of these commitments.
The more interesting question lies elsewhere.
How should a company manage chemical substances when science is still evolving?
This question goes far beyond LVMH. It concerns the entire cosmetics industry. Yet because of its size, research capacity and global influence, LVMH offers an interesting case study of how multinational companies navigate the increasingly complex landscape of endocrine disruptors.
A moving scientific target
Public debate often gives the impression that chemicals fall into two simple categories: safe or dangerous.
Reality is considerably more nuanced.
Most substances do not suddenly become hazardous the day regulators decide to restrict them. Scientific knowledge accumulates slowly. Experimental studies identify potential biological effects. Independent laboratories attempt to reproduce those findings. Regulatory agencies review hundreds of publications before reaching conclusions. Only after years—sometimes decades—can legislation eventually change.
In other words, regulation is almost always the final step of a much longer scientific process.
For industry, this creates a difficult situation.
Companies must formulate products based on today’s regulatory framework while keeping an eye on tomorrow’s scientific evidence. They operate in a space where certainty is rare and decisions often need to be made before complete consensus exists.
This is precisely why endocrine disruptors have become such a challenging issue.
Unlike acute toxicity, endocrine disruption may involve subtle biological mechanisms, low-dose effects, sensitive periods of development and complex interactions with hormonal systems. As research progresses, substances that once attracted little attention may become the subject of intense scientific debate.
What LVMH says
LVMH’s public documentation reflects an awareness of these challenges.
The Group states that product safety is integrated throughout the development process, from ingredient selection to final formulation. According to its Universal Registration Document and LIFE 360 programme, LVMH combines toxicological expertise, regulatory monitoring and internal governance procedures to identify substances requiring particular attention. The company also reports that it has voluntarily restricted or eliminated certain chemical families ahead of regulatory requirements, including several per- and polyfluoroalkyl substances (PFAS) and specific cyclic silicones used in cosmetics.
This approach illustrates a philosophy of anticipation rather than simple compliance.
It also reflects an important reality: chemical regulation has become increasingly dynamic, and companies capable of anticipating future restrictions are likely to be better prepared for regulatory change.
From a corporate perspective, this is both sound risk management and good business strategy.
But anticipation itself raises another question.
How far should anticipation go?
Should it stop once regulatory expectations have been met?
Or should it extend to emerging scientific evidence that has not yet translated into legislation?
That distinction is becoming increasingly important.
When Scientific Evidence Raises New Questions
One family of ingredients illustrates this challenge particularly well: ultraviolet (UV) filters.
Most consumers associate UV filters with sunscreens. In reality, some of these compounds are also used in other cosmetic applications, where they help protect formulations from light-induced degradation, preserve colour stability or maintain the olfactory characteristics of fragrances over time.
Their function is technical. Their safety, however, continues to be the subject of scientific investigation.
Over the past decade, researchers have devoted increasing attention to the biological activity of several organic UV filters. Some studies have reported endocrine-related effects in laboratory models, while others have explored their environmental persistence, bioaccumulation and potential impact on aquatic ecosystems. None of this automatically means that products containing these substances are unsafe for consumers. But it does illustrate an important point: scientific understanding continues to evolve long after a substance has entered the market.
A study published in Environment International in 2024 is a good example of this evolving knowledge. Researchers exposed zebrafish embryos to four commonly used organic UV filters—avobenzone, benzophenone-3, octocrylene and octyl methoxycinnamate—and observed alterations affecting thyroid hormone regulation, neurodevelopment and kidney-related biomarkers. The authors were careful in their conclusions. Their work does not establish a direct risk for humans. Instead, it highlights biological mechanisms that warrant further investigation and contribute to the broader scientific discussion surrounding endocrine-active substances.
This distinction is essential.
Too often, public debate oscillates between two extremes. Either a substance is portrayed as completely harmless because it remains authorised, or it is immediately described as dangerous because an experimental study has reported biological effects.
Science rarely works in such binary terms.
Experimental models are designed to identify possible mechanisms of action. They provide early signals, not definitive answers. These signals are then weighed alongside exposure data, epidemiological studies, toxicological assessments and real-world conditions before regulatory agencies decide whether existing evidence justifies restrictions.
The process is deliberately cautious.
Yet caution has another consequence.
It inevitably creates a time lag between scientific discovery and regulatory action.
That interval may last several years. During that period, companies continue using ingredients that remain fully compliant with existing legislation while researchers continue publishing new findings.
This is not evidence of regulatory failure. It is simply how modern chemical assessment works.
Another recent study, focusing on the photostability of cosmetic UV filter systems, highlights a different aspect of the same issue. Researchers showed that certain combinations of UV filters become progressively less stable following prolonged exposure to ultraviolet radiation. In particular, formulations combining avobenzone and octyl methoxycinnamate exhibited significant photodegradation, illustrating the technical complexity involved in maintaining both efficacy and stability throughout a product’s shelf life.
For formulators, this creates an engineering challenge as much as a toxicological one.
Every ingredient performs one or several technical functions. Removing or replacing it may affect product stability, colour, texture, fragrance or shelf life. Consequently, substitution is rarely as simple as exchanging one molecule for another.
This is where the discussion becomes particularly relevant for companies such as LVMH.
The Group rightly emphasises scientific expertise and continuous product evaluation. However, the broader question is no longer limited to whether individual ingredients comply with current regulations. It concerns how industrial research should respond when emerging science begins to question substances that remain legally authorised.
Should companies wait until regulatory agencies complete their evaluations?
Or should they integrate emerging evidence into long-term research strategies, even when scientific consensus has not yet been reached?
There is no simple answer.
But for global leaders with significant research capabilities, this question increasingly defines what responsible innovation means in practice.
Beyond Substitution: Is It Time to Rethink Product Design?
Much of today’s discussion about endocrine disruptors revolves around substitution.
When a substance becomes controversial, the objective is clear: identify a safer alternative with similar technical performance. This approach has driven significant progress across the cosmetics industry and remains an essential component of chemical risk management.
Yet substitution may not always represent the final stage of innovation.
Perhaps the more fundamental question is this:
Why is the substance needed in the first place?
Every ingredient exists because it performs a specific function. It stabilises a formulation, prevents oxidation, protects against ultraviolet light, preserves colour, enhances texture or prolongs shelf life.
If that function could be achieved differently, the discussion would no longer be limited to replacing one molecule with another. It would become a question of redesign.
Consider fragrance stability.
Protecting a perfume from ultraviolet radiation is a genuine technical challenge. Exposure to light can alter volatile compounds, modify colour and affect olfactory quality over time. Chemists have developed highly sophisticated formulation strategies to minimise these effects.
But chemistry is not the only possible solution.
Packaging itself can become part of the answer.
Advances in glass technology, UV-filtering coatings, opaque or partially opaque containers, improved storage conditions and new packaging materials all contribute to limiting light exposure before the product ever reaches the skin.
None of these approaches is likely to eliminate the need for stabilising ingredients altogether. Nor would they necessarily be appropriate for every formulation.
However, they illustrate a broader principle that deserves greater attention.
The safest chemical is often the one that never had to be used.
This philosophy lies at the heart of green chemistry and eco-design. Rather than focusing exclusively on replacing substances once concerns arise, it asks whether intelligent product design can reduce the need for certain chemicals altogether.
For a company like LVMH, whose identity is built around innovation and craftsmanship, this perspective offers an opportunity rather than a constraint.
The Group has repeatedly demonstrated its ability to anticipate market trends, invest in scientific research and redesign products to meet changing consumer expectations. Extending this approach to chemical innovation would not simply reinforce regulatory compliance; it could help redefine what leadership in sustainable luxury means.
This is particularly relevant because consumers themselves are changing.
Increasingly, they expect transparency alongside performance. They are no longer interested only in whether a product complies with regulations. They also want to understand how companies evaluate uncertainty, interpret emerging science and decide when precaution becomes appropriate.
These expectations are unlikely to diminish.
If anything, they will probably become one of the defining features of the cosmetics industry over the coming decade.
A Question That Goes Beyond LVMH
Ultimately, this discussion is not about identifying winners or losers.
Nor is it about suggesting that authorised ingredients are necessarily unsafe.
It is about recognising that scientific knowledge is never static.
As new evidence emerges, companies face choices that extend beyond legal obligations. They must decide whether to wait for regulatory certainty or whether to incorporate emerging scientific signals into their long-term innovation strategies.
LVMH is far from the only company facing this challenge.
But as the world’s largest luxury group, its decisions carry particular weight. They influence suppliers, competitors and, in many respects, the direction of the wider cosmetics industry.
That is why examining its approach to endocrine disruptors matters.
Not because it provides all the answers, but because it illustrates a broader transformation taking place across the sector.
The future of chemical safety will not depend solely on identifying hazardous substances or replacing controversial ingredients.
It will depend on something more ambitious: designing products that require fewer substances of concern in the first place.
Perhaps that is the next frontier of sustainable innovation.
Not replacing chemicals.
Needing fewer of them.
This debate would have been strengthened by LVMH’s participation. Throughout this campaign on endocrine disruptors in cosmetics, the Group has been invited on several occasions to engage in an open discussion on these issues.
To date, no response has been received. As the global leader in luxury goods, with significant scientific and financial resources, LVMH is uniquely positioned to help shape the future of safer and more sustainable product design.
Its perspective would have been a valuable contribution to a conversation that goes far beyond regulatory compliance and concerns the future direction of the cosmetics industry.
References
- Kwon BR, et al. (2024). Thyroid, neurodevelopmental, and kidney toxicities of common organic UV filters in embryo-larval zebrafish (Danio rerio), and their potential links. Environment International, 192, 109030.
- Scientific Committee on Consumer Safety (SCCS). Opinions on UV filters used in cosmetic products.
- LVMH. Universal Registration Document 2025. Chapters: LIFE 360, Product Safety, Ingredient Charter, Chemical Management.
- LVMH. LIFE 360 Environmental Programme.
- European Commission. Regulation (EC) No 1223/2009 on Cosmetic Products.
- European Chemicals Agency (ECHA). Guidance on endocrine disruptors and substances of very high concern.